bluebird bio
NEWS
This morning, the companies announced the regulatory agency issued a Refusal to File letter regarding the BLA for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pretreated relapsed and refractory multiple myeloma.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
The deal will last three years, with a top priority to develop a gene therapy for hemophilia A.
In the latest Ideal Employer Survey, BioSpace readers chimed in their thoughts on which companies across the biotech and biopharma industries were doing the most interesting and meaningful work.
JOBS
IN THE PRESS
bluebird bio, Inc. (NASDAQ: BLUE) today announced members of the management team will participate in the Canaccord Genuity 40 th Annual Growth Conference, Wednesday, August 12, at 10:30 a.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com . A rep
89% of evaluable patients (17/19) with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype achieved transfusion independence with 11.9 g/dL median weighted average total hemoglobin (Hb) level in HGB-207
99.5% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with a history of VOCs and ACS (n=14) who had at least six months follow-up
bluebird bio, Inc. announced that, due to the public health and safety concerns related to the novel coronavirus pandemic, to support the health and well-being of its directors, employees and stockholders, the location of the Company’s 2020 Annual Meeting of Stockholders has been changed to a virtual format only.
bluebird bio, Inc. (NASDAQ: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 12 at 8:00 am ET. Investors may listen to the call on June 12, 2020 at 8:00 am ET by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conferenc
bluebird bio, Inc. announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts.
bluebird bio, Inc. announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent of the shares of common stock offered in the public offering.
bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25 th European Hematology Association Annual Congress Presentation of new and updated results from ongoing Phase 1/2 HGB-206 study of LentiGlobin for sickle cell disease will include additional patients treated in the study New and updated data, including analysis of healthy red blood cell production in patients with transfusion-dependent β-thalassemia
Bristol Myers Squibb and bluebird bio, Inc. announced updated results from the pivotal, Phase 2 KarMMa study evaluating the efficacy and safety of the companies’ investigational B-cell maturation antigen -directed chimeric antigen receptor T cell immunotherapy, idecabtagene vicleucel, in patients with relapsed and refractory multiple myeloma.
Bristol Myers Squibb to host an investor call today at 8:00 a.m. EDT bluebird bio to host an investor call today at 8:45 a.m. EDT